Azacitidine,Magrolimab,Venetoclax
Gilead,Roche,Abbvie
['magrolimab', 'leusm', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'novo ', 'imab ']
#ash22 #leusm daver: aza/ven/magro orr 72% in frontline (64% in tp53m vs 91% in tp53wt), median dor not reached yet with median f/up 14.5m. less favorable resp in secondary aml (dor 2-6m w/wo tp53m). avm appears superior to hma/ven. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)